Minor neuropsychological deficits indicate risk for progression to Alzheimer’s disease
Oct 13, 2023
For patients with subjective cognitive decline, those with minor neuropsychological deficits have increased cognitive decline and a risk for progression to mild cognitive impairment.
Self-, partner-reported cognitive decline linked to tau
May 30, 2024
Significant associations were seen between self- and study partner-reported Cognitive Function Index and tau driven by elevated Aβ.
Differences ID’d in tau burden in Down syndrome, Alzheimer’s disease
Apr 25, 2024
Differences in spatial distribution, timing and magnitude of tau burden were seen for two genetic forms of Alzheimer’s disease.
Higher education may protect functioning with Alzheimer’s disease
Apr 03, 2024
The findings were seen among African American individuals, with greater protective effect in APOE ɛ4 noncarriers.
Lower Alzheimer’s risk seen with PDE5i initiation for erectile dysfunction
Feb 08, 2024
The greatest reduction in risk was seen for those receiving 21 to 50 phosphodiesterase type 5 inhibitor prescriptions.
Transcranial direct current stimulation beneficial in Alzheimer’s disease
Dec 07, 2023
Active tCDS improves cognitive functions in memory domain, including word recall, recall of test instructions and word recognition.
FDA delays decision on new Alzheimer’s drug
Mar 08, 2024
Instead of approving the new Alzheimer’s drug donanemab this month, as was expected, the U.S. Food and Drug Administration will now require the experimental medication be scrutinized more closely...
Timing of CSF biomarker divergence for Alzheimer’s disease, normal cognition varies
Feb 21, 2024
Estimated times of divergence of cerebrospinal fluid biomarkers vary from 18 years for Aβ42 to six years for cognitive decline.
Biogen is dropping controversial Alzheimer’s drug Aduhelm
Jan 31, 2024
Biogen said it will shift its focus to a newer Alzheimer’s drug, Leqembi, which it markets in a partnership with Japan-based Eisai. Leqembi received FDA approval last year.
Vasomotor symptoms linked to increased risk for Alzheimer’s disease
Sep 27, 2023
Objectively assessed VMS (so-called hot flashes), including sleep VMS, are associated with significantly lower amyloid-β42/40.